Skye Bioscience Inc (SKYE) - News Archive

Skye Bioscience Strengthens Talent Pool with Inducement Grants and Strategic Board Appointment Amidst Market ChallengesOverview of Recent Developments at Skye BioscienceIn a significant move to enhance its workforce and...

Skye Bioscience Inc. a trailblazer in the innovative realm of cannabinoid-based therapeutics, is gearing up for a significant year in 2025. As the company looks to unveil important Phase 2 clinical trial data related to...

In an impressive leap towards addressing the growing global obesity epidemic, Skye Bioscience, Inc. (Nasdaq: SKYE) has announced that it has surpassed the 50% patient enrollment mark in its Phase 2 clinical study known...

Unlocking Potential Amidst Challenges: Skye Bioscience to Share Third Quarter 2024 Results In an era of rapid advancements and transformative breakthroughs, Skye Bioscience, Inc. stands at the nexus of innovation and re...

In the grand tapestry of medical advancement, where the delicate threads of hope and despair often intertwine, the esteemed Skye Bioscience Inc. emerges as a daring voyager navigating the tempestuous seas of clinical tr...

By City, - Skye Bioscience, a clinical-stage biopharmaceutical company dedicated to uncovering innovative therapeutic avenues for metabolic health, has recently announced the appointment of Dr. Puneet S. Arora as its ne...

SAN DIEGO, Aug. 23, 2024 - Skye Bioscience, a clinical-stage biopharmaceutical company specializing in discovering innovative therapeutic pathways for metabolic health, has announced the granting of a non-qualified stoc...

In an exciting development in the field of obesity treatment, Skye Bioscience has announced the launch of its Phase 2 clinical trial, known as the CBeyond trial, to evaluate the efficacy and safety of its innovative CB1...

In a compelling virtual Key Opinion Leader (KOL) event, Skye Bioscience recently unveiled comprehensive insights into their innovative work on metabolic rewiring via CB1 inhibition. Central to the event was the detailed...

In recent weeks, Skye Bioscience Inc s shares have shown a significant under-performance compared to the overall market. This article aims to examine the key events and factors that may have contributed to this decline....

Renowned Clinicians and Academics Join Skye Bioscience s Metabolic Clinical and Scientific Advisory Board to Drive the Development of NimacimabSkye Bioscience, a biopharmaceutical company focused on advancing innovative...

Word Count: 701In the pharmaceutical industry, stock performance often mirrors the financial health and prospects of a company. In recent events, Skye Bioscience Inc, a clinical-stage biopharmaceutical company, has expe...

Throughout the month, Skye Bioscience Inc shares have been trailing the performance of the entire market. However, recent developments suggest potential for growth and improvement in the company s outlook. This article...

Seasoned industry veteran adds significant global biotech and biopharma experience to Skye s Board of DirectorsIn a major development for Skye Bioscience, Inc. (Nasdaq: SKYE), a clinical-stage biotechnology company focu...

Skye Bioscience Gains Prestigious Inclusion in Russell 2000 and Russell 3000 IndexesSAN DIEGO, July 01, 2024 - Skye Bioscience, Inc. (Nasdaq: SKYE), a leading clinical-stage biotechnology company specializing in the dis...

Skye Bioscience Shifts Focus Amidst Mixed Results in Ophthalmic Emulsion Trials and Announces Presence at ARVO 2024 Annual Meeting Skye Bioscience, Inc. (Nasdaq: SKYE), a clinical-stage biotechnology company dedicated t...

In the dynamic sphere of pharmaceutical sciences, the continual pursuit of innovative therapeutic innovations remains pivotal for alleviating global health issues. Substantial strides have been made through biotechnolog...

In a recent announcement, Skye Bioscience, Inc. revealed that it will be presenting two posters at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place from May 5th to 9th in...

Skye Bioscience, a pharmaceutical company specializing in targeting the endocannabinoid system, recently announced that it has treated the first patient in its Phase 2 clinical trial for SBI-100 Ophthalmic Emulsion (OE)...